Finding might hold answer to preventing lung disease in cystic fibrosis

May 27, 2013

(Medical Xpress)—Researchers at the Institute, Queensland Children's Medical Research Institute (QCMRI), and the Telethon institute for Child Health Research, Perth; are one step closer to preventing serious lung disease which is the main cause of suffering in cystic fibrosis.

is an inherited condition that affects one in 2800 children, with one in 25 people a carrier of the gene that causes the condition. There is no current cure however researchers have been working to prevent the onset of .

The study, which is part of the Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF) program, sought to determine for the onset of bronchiectasis. Bronchiectasis is a progressive and persistent form of lung disease.

Researchers studied 127 infants diagnosed with cystic fibrosis and found that they could determine which children were at most risk of developing bronchiectasis by three years of age.

The study showed children with cystic fibrosis who have neutrophil elastase in their lungs at three months are seven times more likely to develop bronchiectasis by 12 months, and four times more likely by three years.

Neutrophil elastase is one of the body's mechanisms for destroying bacteria in the body.

The levels of neutrophil elastase in the body is normally controlled, however in cystic fibrosis excess neutrophil elastase can cause breakdown of the lung structure. This leads to irreversible like bronchiectasis.

Lead researcher, Professor Sly from QCMIR said, "If we have a mechanism for mopping up neutrophil elastase then we can potentially stop or delay the start of damage to the lungs. We are currently undertaking a clinical trial using which has anti-inflammatory effects to prevent in infants with cystic fibrosis".

The trial, COMBAT CF, is a clinical trial undertaken in Australia and New Zealand which is the first in the world to try and prevent irreversible lung damage early in life.

"We are seeing lung damage in children with cystic fibrosis as young as three months old. Clearly lung disease starts in the first months of life so early intervention is paramount to improving health and quality of life."

This study was a joint collaboration between the Queensland Children's Medical Research Institute under the direction of Professor Peter Sly, The Telethon Institute for Child Health Research under the direction of Professor Stephen Stick and Murdoch Childrens under the direction of Professor Sarath Ranganathan.

The study was published in the New England Journal of Medicine.

Explore further: Azithromycin may provide benefit for treatment of respiratory disorder

Related Stories

Inhaler approved for cystic fibrosis patients

March 25, 2013

(HealthDay)—The TOBI Podhaler (tobramycin inhalation powder) has been approved by the U.S. Food and Drug Administration to treat cystic fibrosis patients infected with Pseudomonas aeruginosa, a bacterium that can damage ...

Recommended for you

Kidney stone? Try a roller coaster ride

September 27, 2016

(HealthDay)—Anyone who's suffered a kidney stone just wants the urinary obstruction gone. Now, preliminary research suggests relief might even be fun: a roller coaster ride.

The 'love hormone' may quiet tinnitus

September 23, 2016

(HealthDay)—People suffering from chronic ringing in the ears—called tinnitus—may find some relief by spraying the hormone oxytocin in their nose, a small initial study by Brazilian researchers suggests.

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.